JP2024546129A - アルファ－ｌ－イズロニダーゼ酵素を含む融合タンパク質及びその方法 - Google Patents

アルファ－ｌ－イズロニダーゼ酵素を含む融合タンパク質及びその方法 Download PDF

Info

Publication number
JP2024546129A
JP2024546129A JP2024534711A JP2024534711A JP2024546129A JP 2024546129 A JP2024546129 A JP 2024546129A JP 2024534711 A JP2024534711 A JP 2024534711A JP 2024534711 A JP2024534711 A JP 2024534711A JP 2024546129 A JP2024546129 A JP 2024546129A
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
identity
idua
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534711A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546129A5 (enExample
Inventor
ゴウリスダ アドゥスミリ，
オリバー ブレイアー デイビス，
ミハリス エス． カリオリス，
カタル エス． マホーン，
シュリシュティ ティヤギ，
繭輔 山ノ口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JP2024546129A publication Critical patent/JP2024546129A/ja
Publication of JP2024546129A5 publication Critical patent/JP2024546129A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024534711A 2021-12-17 2022-12-16 アルファ－ｌ－イズロニダーゼ酵素を含む融合タンパク質及びその方法 Pending JP2024546129A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163291283P 2021-12-17 2021-12-17
US63/291,283 2021-12-17
PCT/US2022/053196 WO2023114485A1 (en) 2021-12-17 2022-12-16 Fusion proteins comprising alpha-l-iduronidase enzymes and methods

Publications (2)

Publication Number Publication Date
JP2024546129A true JP2024546129A (ja) 2024-12-17
JP2024546129A5 JP2024546129A5 (enExample) 2026-01-07

Family

ID=85175822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534711A Pending JP2024546129A (ja) 2021-12-17 2022-12-16 アルファ－ｌ－イズロニダーゼ酵素を含む融合タンパク質及びその方法

Country Status (12)

Country Link
US (1) US20250136963A1 (enExample)
EP (1) EP4448746A1 (enExample)
JP (1) JP2024546129A (enExample)
KR (1) KR20240119118A (enExample)
CN (1) CN118401660A (enExample)
AR (1) AR128003A1 (enExample)
AU (1) AU2022415476A1 (enExample)
CA (1) CA3241240A1 (enExample)
IL (1) IL313553A (enExample)
MX (1) MX2024007319A (enExample)
TW (1) TW202340459A (enExample)
WO (1) WO2023114485A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020252554B2 (en) 2019-04-03 2026-05-28 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
TW202542190A (zh) * 2023-12-20 2025-11-01 美商戴納立製藥公司 包含酸性α—葡萄糖苷酶之融合蛋白及其方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017534640A (ja) * 2014-11-10 2017-11-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルファ−ｌ−イズロニダーゼ、イズロン酸−２−スルファターゼおよびアルファガラクトシダーゼａの治療用組成物ならびにそれらの使用方法
CA2990785C (en) * 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
EP4628586A3 (en) 2017-02-17 2026-01-14 Denali Therapeutics Inc. Transferrin receptor transgenic models
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
WO2019246071A1 (en) * 2018-06-18 2019-12-26 Denali Therapeutics Inc. Fusion proteins comprising progranulin
WO2021158986A1 (en) * 2020-02-07 2021-08-12 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome

Also Published As

Publication number Publication date
TW202340459A (zh) 2023-10-16
CA3241240A1 (en) 2023-06-22
IL313553A (en) 2024-08-01
EP4448746A1 (en) 2024-10-23
WO2023114485A1 (en) 2023-06-22
CN118401660A (zh) 2024-07-26
KR20240119118A (ko) 2024-08-06
AR128003A1 (es) 2024-03-20
MX2024007319A (es) 2024-07-22
US20250136963A1 (en) 2025-05-01
AU2022415476A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
JP7854267B2 (ja) 酵素補充療法用酵素を含む融合タンパク質
US11884944B2 (en) Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
JP2023123757A (ja) トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法
CN107683287B (zh) 用于治疗肌肉萎缩疾病的新型杂合actriib配体陷阱蛋白
JP2019535675A (ja) 新規なハイブリッドａｃｔｒｉｉｂリガンドトラップタンパク質を用いた筋消耗及び骨疾患の治療方法
CN113785054A (zh) 包含艾杜糖醛酸2-硫酸酯酶的蛋白质分子制剂
JP2021527656A (ja) プログラニュリンを含む融合タンパク質
US20250136963A1 (en) Fusion proteins comprising alpha-l-iduronidase enzymes and methods
JP2024507118A (ja) 抗トランスフェリン受容体融合タンパク質及びその使用方法
US12378540B1 (en) Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof
HK40114509A (en) Fusion proteins comprising alpha-l-iduronidase enzymes and methods
WO2023108137A1 (en) Modified actriib proteins and methods of use thereof
EA051395B1 (ru) Слитые белки, содержащие ферменты сульфоглюкозамин-гидролазы, и связанные с ними способы
HK40103089A (en) Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
WO2026006173A1 (en) Fusion proteins comprising modified glucocerebrosidase polypeptides and methods thereof
EP4634218A2 (en) Methods and compositions related to engineered transferrin receptor-binding molecules
WO2024220986A2 (en) Methods of increasing sialic acid levels in recombinant glycosylated proteins
AU2024267726A1 (en) Cd200 fusion proteins
HK40064377A (en) Formulations of protein molecules comprising iduronate 2-sulfatase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251203